<DOC>
	<DOCNO>NCT02198313</DOCNO>
	<brief_summary>The objective present study obtain information safety tolerability multiple increase dos BIIX 1 XX obtain preliminary pharmacokinetic data</brief_summary>
	<brief_title>A Multiple Increasing Dose Safety Tolerability Study After Inhalation Administration BIIX 1 XX Healthy Male Volunteers</brief_title>
	<detailed_description />
	<criteria>Healthy male volunteer BrocaIndices within +20 % Participants age range 21 50 year In accordance Good Clinical Practice ( GCP ) local legislation volunteer suppose give write informed consent prior admission study . Subsequently subject receive complete medical examination ( include blood pressure , pulse rate , medical history , documentation demographic , inclusion/exclusion criterion concomitant therapy ) well 12lead Electrocardiogram ( ECG ) Haematopoietic , hepatic renal function test carry laboratory The subject fast 12 hour collection specimens laboratory evaluation . The mentioned examination perform within 14 day first administration test substance Any finding medical examination ( include blood pressure , pulse rate ECG ) laboratory test deviate form normal clinical relevance Gastrointestinal , hepatic , renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder Diseases central nervous system ( epilepsy ) psychiatric disorder History orthostatic hypotension , faint spell blackouts Chronic relevant acute infection History allergy/hypersensitivity ( include drug allergy ) deem relevant trial judge investigator Intake drug long halflife ( &gt; = 24 hour ) within least one month less ten halflives respective drug enrolment study Use drug might influence result trial within seven day prior administration trial Participation another trial investigational drug within last two month prior start study Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) Inability refrain smoke study day History alcohol abuse and/or alcohol abuse Drug abuse Blood donation ( &gt; 100 ml ) within four week prior administration Other disease abnormality clinical relevance Excessive physical activity within two week prior administration trial</criteria>
	<gender>Male</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>